On Friday, iTeos Therapeutics got a positive adjustment to its Relative Strength (RS) Rating, from 70 to 76.
Can You Really Time The Stock Market?
IBD's unique rating tracks share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 in the early stages of their moves. See if iTeos Therapeutics can continue to show renewed price strength and clear that threshold.
While the stock is not near an ideal buying range right now, see if it goes on to form and break out from a proper consolidation.
The company showed 0% EPS growth last quarter. Sales rose -100%.
iTeos Therapeutics holds the No. 122 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
